What question did this study set out to answer?

To explore the impact of SGLT2 inhibitors on outcomes in heart failure patients with tricuspid regurgitation.

April 1, 2026Open Access

Heart Failure and Tricuspid Regurgitation: The Role of SGLT2 Inhibitors in Improving Outcomes

Key Result

SGLT2 inhibitor therapy is associated with improved outcomes and attenuated tricuspid regurgitation progression in patients with heart failure.

Key Points

To explore the impact of SGLT2 inhibitors on outcomes in heart failure patients with tricuspid regurgitation.
Analyzed data from a high-risk population with heart failure
Evaluated associations between SGLT2 inhibitors and tricuspid regurgitation progression
Used observational design for the study
SGLT2 inhibitors are linked to improved outcomes in heart failure patients
Attenuation of tricuspid regurgitation progression is observed
The findings highlight the limitations of observational data and possible confounding factors

Structured PICO

Does SGLT2i therapy improve outcomes and attenuate TR progression in patients with heart failure and significant tricuspid regurgitation?

Population

Patients with heart failure and significant tricuspid regurgitation

Intervention

SGLT2 inhibitors

Outcome

Clinical outcomes and tricuspid regurgitation (TR) progression

SGLT2 inhibitors may improve clinical outcomes and attenuate disease progression in heart failure patients with significant tricuspid regurgitation, though randomized data is needed.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Significant TR portends worse prognosis in HF. SGLT2i therapy is associated with improved outcomes and attenuated TR progression in this high-risk population, with findings limited by the observational design and potential residual confounding.

Read Full Paperexternally

Mark Helpful

Bookmark

Relay

View Full Paper